Autolus' obe-cel shows sustained responses in Phase 1 trial for severe lupus
AUTL•Autolus Therapeutics presented longer-term Phase 1 CARLYSLE results for obe-cel in severe, refractory systemic lupus erythematosus. Most of 15 participants achieved remission, kidney responses were observed without severe renal flares, and follow-up in adults extended to 25 months.
1. Longer-term trial results
Autolus Therapeutics presented longer-term Phase 1 CARLYSLE results for obe-cel in severe, refractory systemic lupus erythematosus. Most participants achieved disease remission despite severe baseline disease, and kidney responses were observed without severe renal flares. The therapy was well tolerated in 15 patients, with no severe cytokine release syndrome or specified neurological and inflammatory complications observed. Adult follow-up extended to 25 months; obe-cel is being evaluated in the Phase 2 LUMINA trial for lupus nephritis.
